CARDIOVASCULAR JOURNAL OF AFRICA • Vol 24, No 7, August 2013
AFRICA
279
2013;
24
(3): 224–230.
6.
Obata JE, Nakamura T, Kitta Y, Saito Y, Sano K, Fujioka D, Kawabata
KI,
et al
. In-stent restenosis is inhibited in a bare metal stent implanted
distal to a sirolimus-eluting stent to treat a long de novo coronary lesion
with small distal vessel diameter.
Catheter Cardiovasc Interv
2013.
2013 Feb 4. doi: 10.1002/ccd.24841. [Epub ahead of print].
7.
Otake H, Honda Y, Courtney BK, Shimohama T, Ako J, Waseda K,
Macours N,
et al
. Intravascular ultrasound results from the NEVO
ResElution-I trial: a randomized, blinded comparison of sirolimus-
eluting NEVO stents with paclitaxel-eluting TAXUS Liberté stents in
de novo native coronary artery lesions.
Circ Cardiovasc Interv
2011;
4
(2): 146–154.
8.
Jiménez-Quevedo P, Sabaté M, Angiolillo DJ, Costa MA, Alfonso
F, Gómez-Hospital JA, Hernández-Antolín R,
et al.
; DIABETES
Investigators. Vascular effects of sirolimus-eluting versus bare-metal
stents in diabetic patients: three-dimensional ultrasound results of the
Diabetes and Sirolimus-Eluting Stent (DIABETES) Trial.
J Am Coll
Cardiol
2006;
47
(11): 2172–2179.
9.
De Luca G, Dirksen MT, Spaulding C, Kelbæk H, Schalij M, Thuesen L,
van der Hoeven B,
et al.
; DESERT Cooperation. Meta-analysis compar-
ing efficacy and safety of first generation drug-eluting stents to bare-
metal stents in patients with diabetes mellitus undergoing primary percu-
taneous coronary intervention.
Am J Cardiol
2013;
111
(9): 1295–1304.
10. Bangalore S, Kumar S, Fusaro M, Amoroso N, Kirtane AJ, Byrne RA,
Williams DO,
et al
. Outcomes with various drug eluting or bare metal
stents in patients with diabetes mellitus: mixed treatment comparison
analysis of 22,844 patient years of follow-up from randomised trials.
Br Med J
2012;
345
: e5170.
11. Sinning JM, Baumgart D, Werner N, Klauss V, Baer FM, Hartmann F,
Drexler H,
et al.
; SCORPIUS Study. Five-year results of the Multicenter
Randomized Controlled Open-Label Study of the CYPHER Sirolimus-
Eluting Stent in the Treatment of Diabetic Patients with De Novo Native
Coronary Artery Lesions (SCORPIUS) study: a German multicenter
investigation on the effectiveness of sirolimus-eluting stents in diabetic
patients.
Am Heart J
2012;
163
(3): 446–453.
12. Aoki J, Ong A, Rodriguez-Granillo G, Van Mieghem C, Daemen J,
Sonnenschein K, McFadden E,
et al
. The efficacy of sirolimus-eluting
stents versus bare metal stents for diabetic patients undergoing elective
percutaneous coronary intervention.
J Invasive Cardiol
2005;
17
(7):
344–348.
13. Maresta A, Varani E, Balducelli M, Varbella F, Lettieri C, Uguccioni L,
Sangiorgio P,
et al.
; DESSERT Investigators. Comparison of effective-
ness and safety of sirolimus-eluting stents versus bare-metal stents in
patients with diabetes mellitus (from the Italian Multicenter Randomized
DESSERT Study).
Am J Cardiol
2008;
101
(11): 1560–1566.
14. Chan C, Zambahari R, Kaul U, Lau CP, Whitworth H, Cohen S,
Buchbinder M; DECODE investigators. A randomized comparison of
sirolimus-eluting versus bare metal stents in the treatment of diabetic
patients with native coronary artery lesions: the DECODE study.
Catheter Cardiovasc Interv
2008;
72
(5): 591–600.
15. Baumgart D, Klauss V, Baer F, Hartmann F, Drexler H, Motz W, Klues
H,
et al.
; SCORPIUS study investigators. One-year results of the
SCORPIUS study: a German multicenter investigation on the effective-
ness of sirolimus-eluting stents in diabetic patients.
J Am Coll Cardiol
2007;
50
(17): 1627–1634.
16. Daemen J, Garcia-Garcia HM, Kukreja N, Imani F, de Jaegere PP,
Sianos G, van Domburg RT,
et al
. The long-term value of sirolimus- and
paclitaxel-eluting stents over bare metal stents in patients with diabetes
mellitus.
Eur Heart J
2007;
28
(1): 26–32.
17. DerSimonian R. Meta-analysis in clinical trials.
Control Clin Trials
1986;
7
(3): 177–188.
18. DerSimonian R. Meta-analysis in the design and monitoring of clinical
trials.
Stat Med
1996
15
(12): 1237–1248.
19. Klebanoff MA, Levine RJ, DerSimonian R. Large trials vs meta-analy-
sis of smaller trials.
J Am Med Assoc
1997;
277
(5): 376–377.
20. Geller N, Freedman L, Lee YJ, DerSimonian R. Conference on meta-
analysis in the design and monitoring of clinical trials.
Stat Med
1999;
18
(6): 753–754.
21. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA group. Preferred
reporting items for systematic reviews and meta-analyses: the PRISMA
statement.
PLoS Med
2009;
6
(7): e1000097.
22. Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, Carpenter
J,
et al
. Recommendations for examining and interpreting funnel plot
asymmetry in meta-analyses of randomised controlled trials.
Br Med J
2011;
343
: D4002.
23. DerSimonian R, Levine RJ.. Resolving discrepancies between a meta-
analysis and a subsequent large controlled trial. J Am Med Assoc 1999;
282
(7): 664–670.
24. DerSimonian R, Kacker R. Random-effects model for meta-analysis of
clinical trials: an update.
Contemp Clin Trials
2007;
28
(2): 105–114.
25. Riley RD, Higgins JP, Deeks JJ. Interpretation of random effects meta-
analyses.
Br Med J
2011;
342
(d549).
26. Moreno SG, Sutton AJ, Thompson JR, Ades AE, Abrams KR, Cooper
NJ. A generalized weighting regression-derived meta-analysis estimator
robust to small-study effects and heterogeneity.
Stat Med
2012;
31
(14):
1407–1417.
27. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analy-
sis.
Stat Med
2002;
21
(11): 1539–1558.
28. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-anal-
ysis detected by a simple, graphical test.
Br Med J
1997;
315
(7109):
629–634.
29. Jiménez-Quevedo P, Hernando L, Gómez-Hospital JA, Iñiguez A,
Sanroman A, Alfonso F, Hernández-Antolín R,
et al
. Sirolimus-eluting
stent versus bare metal stent in diabetic patients: the final five-year
follow-up of the DIABETES trial.
EuroIntervention
2013; 2013 Mar
22. pii: 20120620-01. [Epub ahead of print].
30. Galassi AR, Tomasello SD, Costanzo L, Campisano MB, Barrano
G, Tamburino C. Long-term clinical and angiographic results of
Sirolimus-Eluting Stent in Complex Coronary Chronic Total Occlusion
Revascularization: the SECTOR registry.
J Interv Cardiol
2011;
24
(5):
426–436.
31. De Waha A, Dibra A, Kufner S, Baumgart D, Sabate M, Maresta A,
Schömig A, Kastrati A. Long-term outcome after sirolimus-eluting
stents versus bare metal stents in patients with diabetes mellitus: a
patient-level meta-analysis of randomized trials.
Clin Res Cardiol
2011;
100
(7): 561–570.
32. Kandzari DE, Rao SV, Moses JW, Dzavik V, Strauss BH, Kutryk MJ,
Simonton CA,
et al
; ACROSS/TOSCA-4 investigators. Clinical and
angiographic outcomes with sirolimus-eluting stents in total coro-
nary occlusions: the ACROSS/TOSCA-4 (Approaches to Chronic
Occlusions With Sirolimus-Eluting Stents/Total Occlusion Study of
Coronary Arteries-4) trial.
J Am Coll Cardiol Cardiovasc Interv
2009;
2
(2): 97–106.
33. Byrne RA, Kastrati A. Is there a preferable DES in diabetic patients?
A critical appraisal of the evidence.
Catheter Cardiovasc Interv
2008;
72
(7): 944–949.
34. Thompson SG, Higgins JP. How should meta-regression analyses be
undertaken and interpreted?
Stat Med
2002;
21
(11): 1559–1573.
35. Sterne JA, Egger M. Funnel plots for detecting bias in meta-analysis:
guidelines on choice of axis.
J Clin Epidemiol
2001;
54
(10): 1046–1055.
36. Zwahlen M, Renehan A, Egger M. Meta-analysis in medical research:
potentials and limitations.
Urol Oncol
2008;
26
(3): 320–329.
